Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and Diagnostic Emergency Use Authorizations in April 2020.Read Article
20 Years of Experience
@NancyDvorin has been covering and analyzing the medical device and pharmaceutical industries for more than 20 years. Prior to joining MedTech Strategist, she was the managing editor of several life sciences business publications including In Vivo and Medtech Insight. Earlier in her career, Nancy managed library and information services for a number of multinational corporations.